相关实验视频

Updated: Jul 4, 2025

MEDUSA for Identifying Death Regulatory Genes in Chemo-genetic Profiling Data

MEDUSA for Identifying Death Regulatory Genes in Chemo-genetic Profiling Data

Published on: February 7, 2025

乙胺诱导的SENP8给急性淋巴细胞白血病细胞提供了反药物耐药性

Shuzhang Sun¹, Yixuan Cheng¹, Wanxin Hou²

¹Clinical Research Center, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.

Biochemistry and biophysics reports

|February 5, 2024

概括

在复发性急性淋巴细胞白血病 (ALL) 中,SENP8的表达很高,并促进对埃托 (VP-16) 化疗的耐药性. 向SENP8可以在ALL治疗中克服耐药性.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
生物化学生物化学

背景情况:

化疗是急性淋巴细胞白血病 (ALL) 的标准,但耐药性和复发存在重大挑战.
了解化疗耐药性的机制对于改善ALL治疗结果至关重要.

研究的目的:

调查SENP8在急性淋巴细胞白血病 (ALL) 中化学抵抗中的作用.
探索SENP8在埃托化物 (VP-16) 耐药性的机制及其作为治疗点的潜力.

主要方法:

在复发的ALL标本中分析SENP8表达.
在ALL细胞中SENP8的过度表达和淘汰研究.
评估对埃托化物 (VP-16) 的化学敏感性及其前性作用.
研究SENP8,MDM2和p53之间的相互作用.

主要成果:

在复发的ALL中,SENP8的表达很高.
过度表达SENP8会降低ALL细胞对乙托化物 (VP-16) 的敏感性及其前性作用.
VP-16治疗诱导了SENP8的积累,MDM2的不稳定性和p53的稳定性.
通过SENP8 knockdown,所有细胞都会对VP-16产生敏感.

结论:

在ALL中,SENP8在赋予埃托化物 (VP-16) 耐药性方面发挥着新的作用.
VP-16诱导的SENP8会为药物耐药性产生一个反循环.
准SENP8是一个潜在的策略,可以克服ALL中的VP-16抗性.

关键词:

急性淋巴细胞白血病 (Acute Lymphoblastic Leukemia) 是一种急性淋巴细胞白血病.抗化疗药物耐药性抗化疗药物耐药性这种类型的Etoposide.在 NEDD Dylation 中进行.这就是SENP8的意义.

更多相关视频

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...